A newly published analysis of data from five major clinical trials involving > 6,000 patients has provided us with additional information about circulating tumor cell (CTC) levels as an endpoint for clinical trials. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer | Tagged: cell, ciculating, clinical, count, CTC, endpoint, trial, tumor | 4 Comments »
A newly published study in Clinical Cancer Research has implied the potential development of a completely new and much more accurate way to be able to identify risk for metastatic prostate cancer. … READ MORE …
Filed under: Diagnosis, Management, Risk | Tagged: blood, cell, circulating, count, CTC, megakaryocyte, PSA, tumor | 1 Comment »
In another breaking story from the UK, a company called Angle PLC has announced that its Parsortix diagnostic system can potentially be used to identify men with prostate cancer using a simple blood sample and testing for the presence of circulating tumor cells (CTCs). … READ MORE …
Filed under: Diagnosis, Management, Risk | Tagged: Angle, cell, circulating, CTC, Diagnosis, Parsortix, risk, tumor | Leave a comment »
A paper to be presented at the Genitourinary Cancers Synposium today, suggests that use of a liquid biopsy and analysis of single circulating tumor cells (CTCs) may be helpful in determining therapy for men with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: biopsy, cell, circulating, CTC, liquid, selection, Treatment, tumor | Leave a comment »
A paper in the British Journal of Cancer has offered further validation of the potential roles for liquid biopsies and circulating tumor cells (CTCs) in the management of aggressive forms of prostate cancer (and in related clinical trials). … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: biopsy, cell, circulating, CTC, expression, liquid, PTEN, tumor | 2 Comments »
Back in 2011 we reported a presentation by Scher et al. indicating that circulating tumor cell counts (CTCs) could probably be used to monitor responses to abiraterone acetate (and perhaps other forms of drug therapy) in the treatment of men with metastatic, castration-resistant prostate cancer. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone, activity, cell, circulating, count, CTC, surrogate, tumor | 3 Comments »
There is increasing evidence that circulating tumor cell (CTC) count may be important in assessing the likelihood for an optimal response to treatment with docetaxel-based chemotherapy for men with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: circulating T-cell, count, CTC, prognosis, risk, survival | 5 Comments »
A team of researchers at Duke University have shown that most men with castration-resistant prostate cancer (mCRPC) express multiple epithelial proteins in their circulating T cells (CTCs). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management | Tagged: circulating T-cells, CTC | Leave a comment »
As we have previously reported, the latest analysis of survival data from the pivotal Phase III trial of abiraterone acetate + predisone has shown a slight improvement in the survival benefit for patients treated with abiraterone (Zytiga™). … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: abiraterone, circulating tumor cell, CTC, survival, Zytiga | Leave a comment »
To date there has only been one test available for assay of levels of circulating tumor cells (CTCs) in men with prostate cancer: the CellSearch test made by Veridex. This test is widely recognized to come with a variety of challenges, and the potential of CTCs in assessing risk for progression of prostate cancer (and other cancers) has therefore been limited. … READ MORE …
Filed under: Living with Prostate Cancer, Management | Tagged: circulating tumor cells, circulating tumor stem cells, CTC, CTSC, outcome, prognosis | Leave a comment »
Data from a small Phase II trial of cilengitide suggest that it has minimal clinical effect in the treatment of men with non-metastatic, castration-resistant prostate cancer (CRPC). They also suggest that levels of circulating T-cells (CTCs) are of limited utility in monitoring the progression of this patient group. … READ MORE …
Filed under: Drugs in development | Tagged: castration-resistant, cilengitide, circulating T-cell, CRPC, CTC | Leave a comment »
Circulating tumor cell (CTC) levels have clearly been shown to have relevance to the prognosis of men with metastatic, castration-resistant prostate cancer, but we still know little about their potential importance in men with early stage disease. … READ MORE …
Filed under: Management, Risk | Tagged: circulating tumor cells, CTC, radical prostatectomy | 11 Comments »
Circulating tumor cells (CTCs) have been approved for marketing by the US Food and Drug Administration as a useful prognostic tool for the management of patients with advanced prostate cancer. … READ MORE …
Filed under: Management | Tagged: CellSearch, circulator tumor cell, CTC, prognosis | Leave a comment »
THE "NEW" PROSTATE CANCER INFOLINK 